Testing how genes affect warfarin dosing in Hispanic and Latino adults
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how a person’s genes may affect how they respond to warfarin, a blood-thinner, so dosing can be safer and more accurate. It specifically focuses on Hispanic and Latino adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Be able to understand the study and sign consent
- Have been on warfarin with a “therapeutic INR” at least two clinic visits in a row
- Self-identify as Hispanic or Latino
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people process warfarin (a blood-thinning medicine) differently. It aims to learn what personal or medication factors may affect how well warfarin works, so future dosing can be safer and more accurate.
This trial tests whether a “point-of-care” computer tool can help clinicians use a person’s genetic information to choose safer, better medication decisions. It focuses on helping reduce treatment differences for African American patients.
This study looks at how your genes affect the way your body handles medications. It aims to improve treatment by understanding genetic differences, especially if you take multiple medications.
This study looks at how “blood marker” results relate to how well direct oral blood thinners (NOACs) and ticagrelor work, and how likely bleeding might be. If you take these medicines for heart or clot conditions, the trial may help doctors better predict your bleeding risk.
This study tests whether a new bedside test (point-of-care testing) can help doctors give you the right dose of warfarin more quickly and safely. If you are starting warfarin for the first time and are in the hospital for a heart problem, you may be eligible.
This study looks at genes and blood function in people with inherited (passed-down) problems with platelets, white blood cells, or blood clotting. It may help improve understanding of the cause of these conditions and how they work in the body.
Hear when a new Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.